We tested the hypothesis that the gastric H+/K+ adenosine triphosphatase inhibitor, omeprazole, because of its different mode of action and pronounced inhibitory effect on gastric acid secretion, may be more effective in peptic ulcer that is refractory to histamine H2 receptor antagonist treatment than continuing the same therapy. Altogether 107 patients (duodenal ulcer, n=88; prepyloric ulcer, n=14; gastric ulcer, n=3; mixed sites, n=2) with refractory peptic ulcer -that is ulcer unhealed after at least two months' treatment with cimetidine 0-8 g or 1 g daily or with ranitidine 0.3 g dailywere randomly allocated to receive either omeprazole 40 
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We tested the hypothesis that the gastric H+/K+ adenosine triphosphatase inhibitor, omeprazole, because of its different mode of action and pronounced inhibitory effect on gastric acid secretion, may be more effective in peptic ulcer that is refractory to histamine H2 receptor antagonist treatment than continuing the same therapy. Altogether 107 patients (duodenal ulcer, n=88; prepyloric ulcer, n=14; gastric ulcer, n=3; mixed sites, n=2) with refractory peptic ulcer -that is ulcer unhealed after at least two months' treatment with cimetidine 0-8 g or 1 g daily or with ranitidine 0.3 g dailywere randomly allocated to receive either omeprazole 40 mg daily (n=54) or to continue treatment with the same H2 receptor antagonist and at the same dose (n=53) for up to eight weeks. The patients in the two treatment groups were well matched demographically. Healing by 'intent to treat' analysis was as follows: at four weeks, omeprazole 46 of 54 (85%), H, receptor antagonist 18 of 53 (34%) (p<0-0001); and at eight weeks, 52 of 54 (96%) and 30 of 53 (57%) respectively (p<0.0001). One patient was lost to follow up but of the 22 patients whose ulcers were shown to be unhealed at endoscopy after receiving continued H, receptor antagonist treatment, 21 healed in four to eight weeks when changed to omeprazole. Daytime epigastric pain cleared at four weeks in 43 of47 (91%) patients on omeprazole and in 32 of46 (70%) on H2 receptor antagonists (p=0.Ol) and relief of all dyspeptic symptoms occurred in 39 of 47 (83%) and 23 of 45 (51%) (p=0.0009) patients respectively. Adverse events occurred in 11 The double blind phase of treatment lasted up to eight weeks. Endoscopy was done at four weeks (± five days) and if the disease was still active the treatment was continued and endoscopy was repeated at eight weeks (±seven days). Those patients whose ulcer(s) was still present then received open treatment with omeprazole 40 mg daily for a further four weeks, without the treatment code being broken, and endoscopy was repeated. Healing was defined as the complete epithelialisation of the ulcer(s). At each endoscopy, biopsy specimens were taken from patients with gastric and prepyloric ulcers to exclude malignancy.
At each visit patients were asked if they had had any ulcer symptoms in the previous two days (daytime and night time epigastric pain, heartburn, nausea, vomiting, bleeding) and inquiries were made of any adverse events (patients were told at the time of trial inclusion to report any such event immediately). Antacid consumption over the previous two days was noted. The unused trial drugs were collected and counted to provide a guide to compliance (non-compliance being defined as using less than 75% of the H2 receptor antagonist or omeprazole) and fresh drugs were issued. Finally, a physical examination was done at the start and at the end of the trial.
STATISTICAL ANALYSIS
In effect, there were three subgroups of patients randomised according to whether before trial entry they were on ranitidine or on cimetidine, the latter used in two doses. (TABLE I) One hundred and seven patients were entered into the study from three centres (40, 34, and 33 patients from each of the centres). In one centre (UK) patients were predominantly on cimetidine 1 g daily before trial entry, but cimetidine 0-8 g and ranitidine 0 3 g daily were used in the other two. Fifty three patients continued their H2 receptor antagonist treatment (cimetidine n= 35, ranitidine n= 18) and 54 were assigned to omeprazole treatment.
Results

NUMBERS OF PATIENTS ENTERED AND EXCLUSIONS FROM ANALYSIS
All 107 patients were included in the intent to treat analysis at four weeks and eight weeks but for per protocol analysis, 93 and 99 patients' data were analysed at these times respectively. The reasons for excluding 15 patients from per protocol analysis (14 at week four and eight at week eight) are shown in Smoking (g/day) (mean(SD)) 9.4(9.9) 9.3 (15-0) 10-9 (9-7) 11-9(8-8) 10-4 (9-7) 11-0 (11-2) Drinking (U/week) (mean (SD)) 9-8 (23.9) 5-6 (9.7) 9-6 (15-9) 13-0 (17-9) 9.0 (18-6) 10-5 (15-9) Previous surgery (perforation repair) 0 H2 receptor antagonists there were considerable differences, the lowest healing rates being observed in Sweden. Thus, by intent to treat analysis the healing rates on omeprazole at four weeks in Rotherham, Linkoping and Milan were 86%, 88%, and 82%, and on H2 receptor antagonists the rates were 47%, 12%, and 41% respectively. Healing rates on cimetidine and ranitidine were roughly similar. Thus, by per protocol analysis, at four weeks healing rates (and 95% confidence intervals for the difference in true healing rates) were: omeprazole 13 of 17 (76%) v ranitidine 6 of 18 (33%) (CI+ 13%-+73%); and at eight weeks: 18 of 18 (100%) v 12 of 17 (67%) (CI+5%-+54%) respectively. The corresponding figures for patients on omeprazole v cimetidine were: at four weeks, 28 of 30 (93%) v 12 of 28 (43%) (CI 30%-70%); and at eight weeks, 33 of 34 (97%) v 16 of 30 (53%) (CI 25%-63%), respectively.
Neither ulcer size or drinking habits were found to have an influence on ulcer healing. No appreciable differences were observed in omeprazole treated patients, but among patients who continued with H2 receptor antagonist treatment, healing was higher in smokers than in nonsmokers (48% v 20%) and lower in those with an ulcer history of < 12 months than in those with a history >12 months (29% v 41%) but the differences were not significant. The only factor which had a significant bearing on the outcome was the drug used.
SYMPTOM RELIEF
The degree and rapidity of pain relief was not a primary objective in this study; indeed a relatively high proportion of patients were symptom free at entry. Daytime epigastric pain was the commonest symptom. It was absent at randomisation in 16 and all the patients with such events were from one centre which recruited cimetidine treated patients. There were no serious adverse events and no patients were withdrawn because ofthem. The commonest problems on omeprazole were mild gastrointestinal disorders -diarrhoea (n=3), loose stools (n=2), and constipation (n= 1). In contrast, the events seen in patients on cimetidine were more diverse with individual patients reporting one of the following: cramps, headache, orchitis, loose stools, nausea, eructation, and greasy skin.
Discussion
Our study has shown that omeprazole (40 mg daily) was significantly better than continued treatment with standard doses of cimetidine (0-8 g or 1 g daily) or ranitidine (300 mg daily) in healing peptic ulcer that was refractory to these doses of H2 receptor antagonists. Though pain control was not a primary objective and patients with extremely severe pain were not included, omeprazole gave better symptom relief than did further H2 receptor antagonist treatment.
Our results support and extend the observation made in open studies18 where healing rates of 90-100% were obtained with omeprazole 40 mg daily. They are, however, at variance with those of the multicentre trial in France'°where the healing rates on omeprazole 20 mg daily and on continued ranitidine 300 mg daily were similar at two weeks -48% and 46% and at four weeks --80% and 75% respectively. The difference may be influenced by three factors. Firstly, although the lower dose of omeprazole (20 mg) used is capable of producing considerable acid inhibition, it does so less consistently than the 40 mg dose. Secondly, in their study resistance was defined as failure to heal after only six weeks' cimetidine treatment. Lastly, patients whose ulcers remained unhealed on cimetidine 800 mg daily were randomised to receive either omeprazole or ranitidine, which in France has previously been shown to be superior to continued cimetidine treatment. " Consideration of the study design is relevant since we had two options for the control armeither to extend H2 receptor antagonist treatment at the same dose despite the failure of treatment at this dosage to heal ulcers in these patients or to double the dose, which would also extend the H2 receptor antagonist treatment period. The latter step has attractions and is commonly used in clinical practice, although without clear evidence of its efficacy. Our experience'2 has shown that continuing the same dose ofH2 receptor antagonist but in a formal clinical trial can be associated with a considerable increase in the healing rate. Indeed, in the present study there was appreciable healing in the group receiving continued H2 receptor antagonist treatment. This effect coupled with a dose increase would confound interpretation. Since our aim was to see if omeprazole was an effective treatment option in this type of patient, we avoided the confusion of changing two variables at once by using continued H2 receptor antagonist treatment as the control arm.
Medical treatment options available until recently in the management of peptic ulcer refractory to H2 receptor antagonists include continued treatment with the same drug at the same dose or at a higher dose9; combining the H2 receptor antagonist with the antimuscarinic, pirenzepine'2'4; or changing to the mucosal protectants, sucralfate'5 or colloidal bismuth subcitrate. Of these measures, the only one that has given clear and unequivocal benefit is colloidal bismuth subcitrate, which in two controlled studies was shown to accelerate healing significantly compared with cimetidine treatment continued at the same dose or at a higher one.'617 We can now extend 'the therapeutic options by including omeprazole 40 mg daily, which heals more than 80% of refractory ulcers within four weeks, and almost all within eight weeks, is effective in relieving pain, and is safe. 
